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Bone metastasis is a frequent finding in the natural history of several types of cancers. However, its anticipated risk,
diagnosis and response to therapy are still challenging to assess in clinical practice. Markers of bone metabolism are
biochemical by-products that provide insight into the tumor–bone interaction, with potential to enhance the clinical
management of patients with bone metastases. In fact, these markers had a cornerstone role in the development of
bone-targeted agents; however, its translation to routine practice is still unclear, as reflected by current international
guidelines. In this review, we aimed to capture several of the research and clinical translational challenges regarding the
use of bone metabolism markers that we consider relevant for future research in bone metastasis.
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Introduction
Bone metastasis (BM) is not only a major topic in the clinical
management of cancer because of its prevalence but is also a
unique subject of cancer research because of the proven
relationship between cancer cells and the stromal cells in bone.
Indeed, BM is the first good example of the importance of the
microenvironment in the metastatic tissue to unravel new
therapeutic targets—the bone-targeted agents (BTAs).
Because of this strong evidence, it was thoughtful to
investigate where we could use bone remodeling biomarkers
to understand the clinical behavior of cancer in bone.
Furthermore, because it is very difficult to undertake useful
objective evaluation of BM by analyzing serial X-rays from bone
surveys or bone scans (BS), the bone remodeling markers
appeared as a logical option to investigate in this context.
Despite the accomplishment of several studies focused to
understand the role of bone remodeling markers to evaluate
BM status,1,2 to monitor treatment response to BTAs and
to anticancer therapy,1,3,4 as well as to predict bone
complications,1 the most adopted guidelines do not recognize a
definitive role for the use of bone remodeling markers to
interpret clinical outcomes and treatment response in patients
with BM.5,6
However, it is intriguing to see that the major clinical trials with
BTAs in phase 2 studies had the bone remodeling markers as
the primary end point. In consequence, several new drugs were
not pursued to phase 3 trials because they did not show
superiority in the bone remodeling marker response. In addition,
the clinical trials with new drugs to treat metastatic prostate
cancer (which often presents with BM) included, as secondary
end point, bone remodeling markers response.7
Finally, because bone remodeling markers can reflect
multiple interactions of cancer cells with osteoclasts and
osteoblasts, they can have a role also in the understanding of
the mechanistic pathways involved in cancer progression in
bone, either in preclinical or in clinical research.
In this review, we aimed to capture several of these aspects
that we consider relevant for future research in BM.
Biochemical Markers of Bone Turnover
Biochemical markers of bone turnover are generally cate-
gorized into bone formation and bone resorption markers.8,9
Bone formation markers include osteoblastic enzymes or
by-products of active osteoblasts during osteoblastogenesis.
The majority of bone resorption markers are by-products of type
I collagen degradation, noncollagenous bone matrix proteins or
osteoclastic enzymes. In addition, several regulators of bone
cells’ activity and thereby bone turnover may also be used as
biomarkers. The biochemical markers of bone turnover are
represented in Figure 1 and summarized in Table 1.
Bone turnover biomarkers used in preclinical and clinical
research of BM include bone-specific alkaline phosphatase
(BALP), osteocalcin (OC), procollagen type I N propeptide
(P1NP), pyridinoline (PYD), deoxypyridoline (DPD), amino-
terminal crosslinked telopeptide of type I collagen (NTX-I) and
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carboxy-terminal crosslinked telopeptides of collagen type I
(CTX-I and ICTP).
BALP is an enzyme specifically produced by osteoblasts
that is involved in mineralization. Its release into circulation
corresponds predominantly to the matrix maturation phase
of bone formation, an intermediate phase of osteoblast
activity.9
OC is a 5.8-kDa noncollagenous protein synthetized by
osteoblasts that binds to hydroxyapatite and is involved in
calcium binding. Glutamic acid residues in OC are converted
to g-carboxyglutamic acid by vitamin K posttranslational
carboxylation, and they are responsible for the calcium binding.
OC is considered a specific marker of osteoblast function.10,11
P1NP is derived from extracellular processing of procollagen
type I molecule. Procollagen contains amino- and carboxy-
terminal extensions that are enzymatically cleaved upon
procollagen secretion, P1NP and P1CP.10
PYD and DPD are two nonreducible pyridinium crosslinks
that are present in bone collagen, which are released into the
circulation upon collagen breakdown either in a free state or
Figure 1 Biochemical markers of bone turnover. Blue boxes/arrows represent bone formation markers: bone-specific alkaline phosphatase (BALP); osteocalcin (OC);
propeptides of type I procollagen (P1NP and P1CP). Orange boxes/arrows represent bone resorption markers: pyridinoline (PYD); deoxypyridoline (DPD); carboxy-terminal
crosslinked telopeptide of collagen type I (CTX-I); amino-terminal crosslinked telopeptide of type I collagen (NTX-I); Hydroxyproline (Hyp); hydroxylysine (Hyl); bone sialoprotein
(BSP); osteopontin (OP); tartrate-resistant acid phosphatase 5b (TRAP5b); cathepsin K. Green boxes represent regulators of bone turnover: receptor activator of NF-kB ligand
(RANKL), osteoprotegerin (OPG), dickkopf-1 (DDK-1) and sclerostin. During the process of bone remodeling, osteoblasts produce RANKL and OPG that regulate the differentiation
and maturation of osteoclasts. Osteoclastic activity is measured by the quantification of its lysosomal enzymes: cathepsin K and TRAP5b. The degradation of bone collagen type-I
releases CTX-I and NTX-I (following degradation by cathepsin K), PYD, DPD and Hyp/Hyl. During the bone resorption process, calcium and enzymes from the bone matrix such as
BSP and OP are released. Bone formation is a process associated with the release of BALP and OC-specific osteoblast enzymes. Osteoblasts secrete to the extracellular space
collagen type I as a procollagen type-I molecule; afterward, its terminals are cleaved releasing P1NP and P1CP. In the presence of DDK-1 and sclerostin, the Wnt pathway is
downregulated and consequently osteoblastic differentiation is inhibited. In bone metastasis (BM), matrix metalloptoteinases (MMPs) are produced by bone stromal cells and bone
metastatic cells. These proteases are able to degrade collagen type-I originating carboxy-terminal crosslinked telopeptide of type I collagen (ICTP).
Table 1 Biochemical markers of bone turnover










Noncollagenous bone matrix proteins: BSP and OP








Abbreviations: BALP, bone-specific alkaline phosphatase; BSP, bone sialoprotein; CTX-I, carboxy-terminal crosslinked telopeptide of collagen type I; DKK-1, dickkopf-1;
DPD, deoxypyridoline; Hyl, hydroxylysine; Hyp, hydroxyproline; ICTP or CTX-MMP, carboxy-terminal crosslinked telopeptide of type I collagen; NF-kB, nuclear factor-kB;
NTX-1, amino-terminal crosslinked telopeptide of type I collagen; OC, osteocalcin; OP, osteopontin; OPG, osteoprotegerin; P1NP and P1CP, propeptides of type I
procollagen; PTH-rp, parathyroid hormone-related peptide; PYD, pyridinoline;RANKL, receptoractivatorof NF-kB ligand; TRAP5b, tartrate-resistantacid phosphatase 5b.
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bound to a peptide. These pyridinium crosslinks result from the
posttranslational modification of lysine and hydrolysine in bone
and represent fragments of crosslinking amino-acid derivatives
that stabilize the collagen type I fibrils in bone.12
The crosslinked telopeptides that are released from type I
collagen degradation by proteases during bone resorption
generate neoepitopes (CTX-I, ICTP, NTX-I). The C-terminal
telopeptide, CTX-I, as well the N-terminal telopeptide,
NTX-I, when compared with ICTP, reflect different enzymatic
pathways of bone breakdown, by cathepsin K or matrix
metalloptoteinase-1 (MMP-1) cleavage of collagen type I,
respectively.13
Inhibitors of Wnt signaling, namely sclerostin and dickkopf-1
(DKK-1), are also considered bone remodeling markers.
Sclerostin is produced by osteocytes, whereas DKK-1 is
produced by osteoblasts and by a variety of different cells in
several tissues, including cancer cells. Both sclerostin and
DKK-1 are secreted into circulation, and serum levels reflect
inhibition of bone formation.14,15
State-of-the-art high-throughput techniques are being used
for the identification of new key biological and molecular
pathways involved in the regulation of bone metabolism.16
Therefore, new bone remodeling markers may emerge in the
future.
Laboratory Determination of Biochemical Markers of
Bone Turnover
Bone remodeling markers reflect the metabolic activities of
osteoclasts (resorption) and osteoblasts (formation) and can be
measured in serum or urine. Available analytical methods for the
determination of bone remodeling markers include enzyme-
linked immunosorbent assay (ELISA), radioimmunoassay (RIA)
and electrochemical luminescence.
Preanalytical and analytical variability in the quantification of
bone remodeling markers represents a major problem in its use
for clinical purposes. In this way, the identification of the
variability sources and the strategies to go beyond this should
be designed. There are two main sources of preanalytical
variability: (1) technical sources, which include sample col-
lection, sample handling and storage, thermodegradation,
photolysis and timing of sample collection (diurnal variation);
and (2) biological sources, such as age, gender ethnicity,
diet, exercise, among others.11,17 To overcome preanalytical
variability, laboratories must establish their own reference
ranges using gender- and age-specific reference values,11
and address intralaboratory reproducibility both in manual
and automated assays.18 The International Osteoporosis
Foundation (IOF) and International Federation of Clinical
Chemistry (IFCC), IOF/IFF working group, have published
recommendations to minimize variability in the determination of
bone remodeling markers.19,20 One bone resorption marker,
serum CTX-I, and one bone formation marker, serum P1NP, are
considered as reference markers and measured by standar-
dized assays in observational and intervention studies. This,
along with the consequent adoption of international reference
standards, allows improving the use of these clinical markers.21
To ensure the integrity of results, laboratories can participate in
external quality assurance schemes. For example, in the United
Kingdom, the External Quality Assessment Service now
includes bone turnover markers in their portfolio.22
Over the past decade, most of the immunoassays that were
used have been automated, contributing to the decrease of
technical variability.18 However, there are specific aspects of
each remodeling biomarker that should be taken into account to
control variability in their quantification.
BALP
The first assays that were developed for the quantification of
BALP were not specific for this isoenzyme; therefore, iso-
enzymes from other organs such as liver could interfere in the
BALP quantification. Since then, different ELISAs have been
developed to quantify BALP isoenzyme in serum or heparin
plasma.10 Although reproducible and precise, these immu-
noassays still retain some crossreactivity with the liver iso-
enzyme: around 15% with the BALP Ostase immunoassay and
3–10% with the Alphase-B enzyme immunoassay. Therefore,
BALP results must be carefully interpreted in patients with liver
pathology.10 Blood withdrawal for BALP quantification must be
performed without ethylenediaminetetraacetic acid (EDTA) or
citrate owing to enzyme inhibition. BALP in serum is stable at
2–8 1C for up to 5 days or at  20 1C for longer storage.23
OC
OC can be quantified by RIA, ELISA or chemiluminescense
immunoassays. Assays that detect the intact OC or large
N-terminal fragments are the most reproducible; however, the
use of this marker is limited owing to high variability.10 OC should
be analyzed in EDTA-derived plasma obtained by immediate
separation after blood withdrawal. OC in plasma is unstable at
room temperature (RT) but stable up to 7 days at 4 1C.17
P1NP
The measurement of P1NP in serum may be of diagnostic
value.11 There are two commercially available assays: manual
Orion RIA detects intact P1NP, whereas the high-throughput
automated Roche Elecsys 2010 analyzer (Hitachi High-Tech-
nologies Corporation, Tokyo, Japan) recognizes both the tri-
meric and thermal degradation forms of P1NP. The automated
method is reported to have better analytical reproducibility.24
P1NP is stable in serum stored up to 48 h at 23–25 1C, up to 76
days at 2–8 1C and up to at least 6 months at  20 to  80 1C.17
PYD and DPD
The measurement of PYD and DPD is not influenced by the
degradation of newly synthetized collagen and only reflects the
degradation of crosslinked mature collagens.11 DYP and DPD
are quantified by reverse-phase high-performance liquid
chromatography in the first or second void urine of the morning,
collected preferentially before 1000 h owing to the diurnal
variation on the concentration of these crosslinks. For long-
itudinal studies, urine should be collected at the same time
point. Creatinine correction of DYP and DPD levels is needed to
control for renal function. Urine samples must be collected
without preservatives, and DYP and DPD are stable at 2–8 1C up
to 7 days or at  20 1C for longer storage.23 The samples should
be protected from light, as PYD and DPD are sensitive to UV
light, resulting in lower concentrations.10
NTX-I
NTX-I is usually quantified in urine, by ELISA, using a mono-
clonal antibody against the a-2 isoform (bone-derived peptide).
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Results must be standardized to creatinine levels, as renal
clearance affects NTX-I excretion. Owing to variations with
circadian rhythm, urine samples should be collected from the
second void of the morning.25 NTX-I is stable in urine collected
without preservatives and stored at RT for up to 24 h, at 2–8 1C
up to 72 h, 3 months when frozen at  20 1C and for at least
1 year at  80 1C. It should be used in less than three freeze/
thaw cycles.23 Urine NTX-I has been the preferred marker in the
clinical setting as, in comparison with serum CTX-I, it is less
sensitive to the circadian rhythm, it is not affected by food intake
and it avoids blood withdrawal.23
CTX-I
With regard to CTX-I, quantification in serum, compared with
urine, is preferable owing to a higher precision throughout
the range of concentrations. ELISA is performed using a
monoclonal antibody against an octapeptide sequence
(EKAHD-b-GGR) in the a-1 (I) chain of the b-isoform. CTX-I
b-isoform is most predominant in mature collagen from bone,
and it results from the isomerization of aspartyl to b-aspartyl
residues. This isomerization occurs with the aging of the
collagen type I molecule.26 Serum CTX-I is affected by food
intake, and blood withdrawal must take place in the fasting
state. Food intake substantially decreases the levels of CTX.27
For this assay, serum should be collected within 3 h after blood
withdrawal and immediately frozen at  20 1C.28
Quantification of CTX-I and NTX-I by ELISA is currently
accurate and reproducible.8 However, for comparison between
samples, the assays should be performed in the same
laboratory, as results from different laboratories, even with
the same test and automated assays, could differ up to
5.6-fold.11,29 Therefore, besides the calibration and the
establishment of references for each laboratory, the ideal
situation to control technical variability is to centralize the
determinations in a unique laboratory.20
ICTP
ICTP, which reflects nonosteoclastic bone resorption mediated
by MMPs, is liberated to the bloodstream during pathological
conditions. Serum ICTP is quantified by RIA,13 and it is relatively
insensitive to changes in bone remodeling mediated by normal
osteoclastic activity. This could be explained by the fact that the
epitope for ICTP antibody used in its quantification by RIA is
cleaved by cathepsin K during normal osteoclastic activity,
becoming unavailable for the quantification. Serum must be
stored at  20 1C, with a decrease of 12% in ICTP levels if kept
at RT for 5 days.11
Preclinical Use of Bone Remodeling Markers
Characterization of bone phenotype in preclinical research
often includes X-rays, bone densitometry, static and
dynamic histomorphometry, biochemical analysis and in vitro
studies.
The histomorphometric analysis is a gold-standard approach
to address bone formation and resorption, as it allows the
quantification and visualization of the mineralizing surface,
mineral apposition rate, bone formation rate, among other
characteristics. Nevertheless, several preclinical studies
focusing on bone remodeling have taken advantage of
the measurement of bone remodeling markers, either to
assess bone development, bone regeneration or bone
pathophysiology. Bone remodeling biomarkers are more
sensitive, discriminative between phenotypes and more
reproducible than histomorphometric measurements. Bio-
chemical markers of bone remodeling have also been used in
preclinical development of antiresorptive agents for bone
metastatic disease in cancer xenograft models.30
Measurement of serum CTX-I by ELISA is a convenient
and the most commonly used approach when using animal
models, when compared with the quantification of NTX-I
in urine.
In several studies, the analysis of three-dimensional bone
microstructural properties by microcomputed tomography,
bone mineral density assessed by X-ray computed tomo-
graphy, histomorphometric analyses and other biochemical
markers such as BALP, OC and tartrate-resistant acid
phosphatase 5b (TRAP5b) have shown consistent results
when compared with CTX-I determination in the serum of
rodents.31–41 In addition, in nonhuman primate models, serum
markers of bone resorption were also consistent with the
observed phenotype.42–46
Biomarkers of bone remodeling can also be used in in vitro
models.47 These cellular models can be reliably used for
enhancing preclinical evaluation of pharmacological agents in
metastatic bone disease. Nevertheless, in the vast majority of
in vitro studies, the determination of osteoclast formation and
activity is usually performed by TRAP staining, TRAP activity,
pit resorption assays and expression of osteoclast-related
markers such as cathepsin K and MMP-9. Osteogenesis is
usually assessed by BALP activity and mineralization assays.
Bone Remodeling Markers in the Clinical Setting
Evaluation of bone metastases development risk after
adjuvant therapy
Even though the majority of patients with recurrent or metastatic
breast and prostate cancers develop BM, a minority does not,
and between those developing BM the timing of such event
differs; therefore, previous studies addressed predictors of
bone involvement. In breast cancer, sub-populations at dif-
ferent risks for BM were identified, as defined by younger age
(o35 years), higher tumor staging (tumor size and nodal
involvement), lower to intermediate histologic tumor grade,
estrogen receptor positivity and previous locoregional or soft
tissue recurrence.48,49 More recently, c-Src activation was also
identified as a gene-expression signature associated with late-
onset BM.50 In prostate cancer, higher PSA levels are also
predictors of bone recurrence.51 Similarly, previous studies
have found an association between specific tumor markers
and bone relapse. Lipton et al.52 retrospectively tested the
association between pretreatment serum level of CTX-I and the
development of bone-only disease relapse in the cohort of
patients enrolled in the NCIC CTG MA.14 study, a phase 3 trial
that tested the added benefit of adjuvant octreotide to
tamoxifen in 667 women with early breast cancer. At a median
follow-up of 7.9 years (123 events of documented disease
recurrence, 19 of which involving the bone as an exclusive site
of metastasis) and after controlling for other significant clin-
icopathologic characteristics, elevated CTX-I was associated
with a shorter bone-only relapse-free survival (hazard ratio (HR)
3.43, 95% confidence interval (CI): 1.20–9.77; P¼ 0.02); of note,
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it was not associated with any other type of recurrence. The
authors hypothesized that an increased tumor metabolism at
baseline may facilitate the development of BM.52,53 In contrast,
Coleman et al.54 did not find such a predictive power of high
CTX-I levels at baseline (CTX-IX0.3 ng ml 1; HR 1.43, 95% CI:
0.87–2.35; P¼ 0.159) when retrospectively analyzing a cohort
of breast cancer patients derived from the AZURE study, a
phase 3 trial testing the added benefit of zoledronic acid (ZA) to
standard adjuvant treatment in 872 patients with stage II/III
breast cancer. Moreover, in this study, P1NP levels at baseline
were also not significantly associated with bone relapse.
Surprisingly, a normal level of serum vitamin D (430 ng ml 1)
was associated with a lower risk of bone relapse (HR 0.11, 95%
CI: 0.02–0.76; P-value¼ 0.0257) and a trend toward a lower risk
of any type of relapse (HR 0.56, 95% CI: 0.31–1.01; P-
value¼ 0.0519). In a smaller study using prospective data from
388 consecutive patients, Diel et al.55 demonstrated that higher
preoperative BSP levels correlate with the development of
bone-only metastases, even when controlling for nodal status
(HR 93.96, 95% CI: 21.65–408.30; Po0.001). By contrast, from
the 14 patients with visceral metastases only, none had
increased BSP. The authors noticed, however, the possibility
that the high levels of BSP might be the result of tumoral
production instead of the result of increased bone turnover.
On the basis of the hypothesis that an increased bone
metabolism may facilitate the development of BM, prior studies
tested the added benefit of ZA in the adjuvant treatment of early
breast cancer. A benefit in terms of relapse-free survival was
found in premenopausal women under complete estrogen
blockage (goserelin with either tamoxifen or anastrazol;
ABCSG-12; Gnant et al.56), in postmenopausal women under
aromatase inhibitors (letrozol; ZO-FAST; Coleman et al.57) and in
women under systemic adjuvant therapy who had undergone
menopause more than 5 years earlier (AZURE; Coleman
et al.58). Moreover, an individual patient data meta-analysis
condensing information from 41 randomized trials that com-
pared bisphosphonates (BPs) with placebo or no BPs in
patients with breast cancer (n¼ 17 016, of which 10 540 were
postmenopausal women) further demonstrated a 34%
improvement in the rate of bone recurrences (Po0.001) and a
novel 17% improvement in the rate of breast cancer death
(P¼ 0.004) in postmenopausal women treated with BPs.59
Pre- or perimenopausal women had no benefit. Importantly,
the hypothesis of enhanced benefit from BPs in those patients
with increased bone metabolism is still lacking support, as
suggested by the previously discussed translational studies
from the AZURE study, in which increased bone turnover levels
at baseline (CTX-I X0.3 ng ml 1) did not predict treatment
benefit.54
Diagnosis of Bone Metastases
BS and conventional radiography (X-ray) are the two most
commonly used imaging methods in the diagnosis of BM;60
however, although BS has low specificity, X-ray has low
sensitivity.60 Thus, based on the broad picture of bone
metabolism provided by bone markers, several authors tested
their role as a diagnostic tool. A comprehensive study included
postmenopausal patients with BM before and after one
administration of different doses of pamidronate (n¼ 19)
compared with pre- and postmenopausal healthy women.
When compared with postmenopausal healthy women, those
with BM had higher levels of urinary calcium, hydroxyproline,
PYD, DPD and CTX-I, but only hydroxyproline, PYD and DPD
were significant.61 After BP therapy, patients were followed up
weekly for 8 weeks (range 4–10). Parameters of bone resorption
declined significantly at week 1, especially CTX-I, and for 63
days for urinary calcium (90% CI: 35–70þ ), 56 days for CTX-I
(21–70þ ), 49 days for hydroxyproline (28–70þ ), 49 days
for DPD (21–70þ ) and 21 days for PYD (14–28 days); on the
other hand, those of bone formation did not change
meaningfully, an effect that reflects the capacity of BPs to
uncouple bone formation and resorption in favor of bone
formation.
Other studies tested the accuracy of several bone markers in
patients with cancer when comparing specifically those with or
without BM. Demers et al.62 tested a panel of seven bone
markers (BAP, PYD, DPD, NTX-I, ICTP, PTH-rp and calcium) in
patients with various types of solid tumors with or without BM,
as defined by BS and/or X-ray bone survey. In this study, urinary
NTX-I, its log transformation (log(NTX-I)) and DPD were the
markers most strongly associated with BM, but only NTX-I and
log(NTX-I) had a relevant discriminating power between those
with BM or local disease only (sensitivity of 0.308 and 0.423,
respectively, and specificity of 0.902, for both). In this cohort,
when comparing markers of bone formation with resorption,
those of bone resorption were most different between the
groups of patients with BM or local disease; nevertheless,
several patients without clinical evidence of BM had also
increased tumor marker levels. The authors speculated that this
elevation may reflect subclinical bone involvement. Wada
et al.63 retrospectively analyzed four bone markers (NTX-I, ICTP,
total ALP and TRAP5b) in 156 breast cancer patients, 23 with
bone-only metastases, 19 with extraosseous-only metastases
and 114 without metastases. Those with BM were further
divided by the number of bone lesions. Contrasting with NTX-I
and total ALP, the mean values of ICTP and TRAP5b were
significantly higher in those patients with BM when compared
with those without (visceral metastases or no metastases), as
were in those with higher bone tumor burden compared with
lower burden and in those with progressive disease despite
therapy compared with those with tumor control. Of note, the
groups above differed in the median age at the time of marker
evaluation, a variable not controlled for in the analysis. On the
other hand, Ulrich et al.3 analyzed a set of three bone markers
(NTX-I, ICTP and BALP) in 106 patients with breast cancer,
either with documented BM (n¼ 19), without BS evidence of BM
(n¼ 65) or with pathologic non-malignant alterations in the bone
scintigram. Tumor marker levels were higher in the group of
patients with BM when compared with the other two groups,
whereas those without clinical evidence of BM had similar
levels. In this cohort, ICTP was the marker with higher sensitivity
(65%), whereas it had similar specificity to BALP (91 vs 92% for
BALP). Given the wide range of values and the lower sensitivity,
the authors concluded that these markers did not allow for early
detection of subclinical bone recurrence and hence the
replacement of imaging techniques for this purpose. Moreover,
bone markers are neither site-specific nor disease-specific;
thus, imaging studies continue to be a key step during the
diagnostic process.
A detailed discussion according to the type of primary tumor
can be found elsewhere.9,64
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Prediction of Patients’ Outcomes
Bone markers have been tested as predictors of skeletal-
related events (SRE), bone disease progression and overall
survival. The retrospective analysis of large data sets derived
from phase 3 clinical trials testing the use of ZA in patients with
BM demonstrated that high baseline bone remodeling markers
levels are adverse prognostic features. Brown et al.4 retro-
spectively studied two bone markers (NTX-I and BALP) in
patients assigned to placebo (control arm) in two phase 3 trials
of ZA. These trials included 441 patients with prostate cancer,
non-small-cell lung cancer (NSCLC) or other cancers,
all with BM. High baseline and on-study NTX-I levels
(X100 nmol mmol 1 creatinine) predicted a higher risk of SRE,
but also a shorter time to first SRE, bone disease progression
and death. Compared with baseline evaluations, on-study
measurements were even more strongly correlated with these
outcomes. Higher BALP levels (X146 IU ml 1) were also
correlated with worse outcomes, excluding bone disease
progression; furthermore, the effect size was smaller. On the
other hand, Coleman et al.65 analyzed the same markers in 1824
BP-treated patients (experimental arm) enrolled in tree phase
3 trials. These trials included patients with several types of
primary solid tumors (mostly breast, prostate and NSCLC) and
multiple myeloma; moreover, patients received either ZA
(n¼ 1462) or pamidronate (n¼ 362). With a median follow-up of
17 months, patients with baseline and on-study urinary NTX-I
levels X50 nmol mmol 1 creatinine had a twofold increased
risk of developing an SRE or having bone disease progression
when compared with those with normal levels
(o50 nmol mmol 1 creatinine). The risk of SRE development
was numerically more pronounced in breast cancer and
lowest in NSCLC, but no interaction was found (P¼ 0.813).
Furthermore, NTX-I levels X100 nmol mmol 1 creatinine were
associated with a four to six times increased risk of death (vs
two to four times for values between 50 and 100 nmol mmol 1
creatinine) when compared with normal levels. Higher levels of
BALP (X146 U l 1) showed a similar association with worse
outcomes but with a heterogeneous correlation by different
primary tumors.
Other studies also demonstrated that early (at 3 months) bone
marker normalization after introduction of ZA is strongly
prognostic. Lipton et al.66 retrospectively analyzed a cohort of
patients treated with ZA in the context of a phase 3 trial
comparing ZA with pamidronate. In this study, early NTX-I
normalization (3 months NTX-I o64 nmol mmol 1 creatinine)
was associated with a significant decrease in the risk of first
SRE (HR 0.504, 95% CI: 0.318–0.798; P¼ 0.0034) and death
(0.454, 95% CI: 0.293–0.704; Po0.001). However, when only
considering the group with an early NTX-I normalization, the
development of a subsequent SRE or death was not always
preceded by an increase in NTX-I levels. Subsequent studies by
the same author using independent data sets found similar
conclusions.67
More recently, denosumab was compared with ZA in patients
with BM from several types of solid tumors and multiple
myeloma;1,68,69 in these studies, denosumab was more
effective delaying time to first and subsequent SRE, which was
correlated with a greater control of bone turnover marker levels
(NTX-I and BALP).1,68
Costa et al.12 further studied the role of bone markers in the
diagnosis of disease progression. In this prospective cohort
study, the authors tested 3 bone markers (NTX-I, ICTP and
BALP) in 123 patients with various metastatic cancers, 26 of
which were extraosseous only (45 bone-only and 52 bone plus
visceral). NTX-I and ICTP, but not BALP, were associated with
bone disease progression (mean increase of 52 and 44%,
respectively; Po0.001 for both), even after controlling for
relevant clinical and demographic characteristics. Moreover,
NTX-I had the highest sensitivity (70%), specificity (80%),
positive (72%) and negative (79%) predictive values for bone
disease progression in the set of markers analyzed (for an
increase X30% from baseline). Curiously, when assessing
ICTP, not only did it increase in the context of bone and
extraskeletal progression, but it also did not decrease with BP
therapy. This led the authors to speculate that ICTP could
represent a bone collagen product derived from an osteoclast-
independent mechanism of bone degradation (MMP-1 action
on bone collagen) and therefore not influenced by BP therapy.
A detailed discussion according to the type of primary tumor
can be found elsewhere.9,64
Dosing of BTAs
The role of bone remodeling biomarkers is mostly acknowl-
edged in the clinical development of BTAs. In phase 2 studies
when comparing denosumab with BPs, the first end point was
the rate of normalization of NTX-I,2,70 as defined as either the
proportion of patients with urine NTX-I lower than 50 nmol l 1
per mM creatinine or the percentage of change in urine NTX-I
corrected for urine creatinine from baseline, both at week 13.2,70
These phase 2 studies were crucial to select the treatment
schedule of denosumab in the three pivotal phase 3 trials that
led to the approval of this new BTA.1,68,69
Despite the evidence that BTAs provide a significant clinical
benefit for patients with BM, these drugs are also responsible
Table 2 Levels of evidence for the use of NTX-I in several settings78
Indication Level of evidence
Preclinical and early clinical development of bone-directed therapies Level I
Predicting bone disease progression, ongoing risk of SREs and mortality Level IIa
Early changes in bone marker levels during bisphosphonate treatment may predict long-term benefits Level II
Detection of bone metastases on an individual basis Level III
Comparing the efficacy of different bone-directed therapies Level III
Guiding the dosing and frequency of bisphosphonate therapy in patients with malignant bone disease Level III
Abbreviations: BALP, bone-specific alkaline phosphatase; CRPC, castration-resistant prostate cancer; NTX-1, amino-terminal crosslinked telopeptide of type I collagen;
SRE, skeletal-related event. Level of evidence grading system, as discussed in previous consensus guidelines.80
aNTX-I in multiple myeloma and breast cancer and BALP in CRPC.
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for relevant adverse events, such as hypocalcemia or osteo-
necrosis of the jaw.71 Moreover, the rate of adverse events
associated with BP treatment increases with time,71 and only
limited evidence assessed long-term use of BPs.12,71 Given the
prompt response of bone markers to treatment with BTAs and
their use as predictors of BTAs efficacy (particularly with ZA),
some authors hypothesized that the serial measurement of
bone markers could be a strategy to tailor therapy regimen.
Actually, the serial measurements of these markers could allow
changing treatment frequency (for example, every 3 months)
and even theoretically allow removing therapy for periods in the
context of optimal bone metabolism control. Currently, treat-
ment guidelines recommend continuing therapy until there is a
substantial decline of patients’ general status6 or even inde-
finitely and throughout the course of the disease;5 however, a
bone marker directed strategy of therapy could maximize
benefits, while decreasing risks and costs. This strategy was
tested in a phase III noninferiority study referred to as the
BISMARK trial,72 in which 289 patients with bone metastases
from breast cancer were randomized to ZA, either as a standard
fixed schedule or under an NTX-I-directed schedule.
Even though the recruitment of patients was lower than planned
(compromising study power), the NTX-I-directed schedule
group had a higher proportion of patients presenting with an
SRE (primary end point HR 1.41, 90% CI: 0.98–2.02; P¼ 0.12),
thus not demonstrating noninferiority of this novel approach. Of
note, patients in the standard schedule had more than double of
ZA administrations and lower median NTX-I values at all
evaluations. Even though underpowered, this study suggested
that an NTX-I-directed schedule may be an unfavorable
strategy. In contrast, two small feasibility studies selected low-
risk patients (as defined by baseline CTXo600 ng l 1 after X3
months of BPs) to receive pamidronate either every 4 or every
12 weeks until CTX failure (4600 ng l 1) or SRE development.
Both trials reported a noninferiority of the 12-week schedule in
this low-risk group.73,74
Two other studies tested the reduction of therapy frequency
from every 4 weeks to every 12 weeks after a treatment period of
B1 year with ZA every 4 weeks.75,76 Both studies reported a
noninferiority of an every 12-week therapy schedule after at
least 1 year of every 4-week ZA in terms of SREs; however,
a significant increase in NTX-I levels from baseline in the every
12-week group was found. The meaning of this increase in the
context of the longer survival of patients with bone metastases
should be further studied. CALGB-70604 and Z-MARK studies,
which are still running, will add further evidence to this topic.
These treatment properties might, however, be specific of BPs,
as a result of its bone matrix accumulation. On the contrary,
denosumab pharmacokinetics may limit this approach.77 It is
noteworthy that an exploratory study comparing several doses
and schedules of denosumab (namely 180 mg every 12 weeks)
with every 4-week BPs showed no difference in the control of
NTX-I or occurrence of SREs.
Conclusion
Bone remodeling markers have been perceived as a valuable
tool to the clinical development of BTAs. The use of bone
remodeling markers in preclinical research is mainly com-
plementary but, in human studies, they have a key role to decide
whether the new BTA is considered a superior alternative to
pursue to a phase 3 level. Further research to determine better
the correlation of different biomarkers with different patterns of
bone degradation observed in the context of BM is advisable to
increase the accuracy of early-phase clinical trials with new
BTAs. In routine clinical practice, bone remodeling markers can
be helpful to define better the prognosis and the risk for bone
complications in patients with BM. However, they are not ready
to be considered as a standard approach in the clinical setting
yet, as shown by the levels of evidence in Table 2. Therefore,
they are not recommended as part of the guidelines.5,6,78
Among many other questions to answer, we believe that more
prospective studies should address the question of whether the
bone remodeling markers could be helpful to decide when to
perform objective evaluation of BM status with BS, bone survey
or even the new imaging tools such as the axial skeleton MRI.
This is probably the most frequent challenge to the clinicians:
BM changes are difficult to evaluate in routine clinical practice.
Indeed, by the RECISTcriteria, BM is usually not a measurable
disease, unless there is a soft tissue mass component evaluable
by CT scan or MRI.79
There is also a need for a more adequate assessment of the
ongoing risk for bone complications after 2 years of BTAs in
long-term survivors. In this setting, together with the clinical
information, the level of bone remodeling markers could add
significant input to decide whether there is a need to continue
BTAs, change the treatment regimen or simply stop the BTAs
until new relevant information appears.
The research in this field should continue, and with the advent
of new treatments affecting the bone microenvironment, such
as radium-223 dichloride (Ra-223) and cabozantinib (a c-met
inhibitor),7,79 a new effort should be taken to define the role of
bone remodeling markers in the assessment of these new
therapies.
Conflict of Interest
The authors declare no conflict of interest.
References
1. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al. Denosumab compared
with zoledronic acid for the treatment of bone metastases in patients with advanced breast
cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132–5139.
2. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR et al. Randomized phase II trial of
denosumab in patients with bone metastases from prostate cancer, breast cancer, or other
neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27: 1564–1571.
3. Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Salzer H et al. Cross-linked type I
collagen C- and N-telopeptides in women with bone metastases from breast cancer. Arch
Gynecol Obstet 2001; 264: 186–190.
4. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M et al. Bone turnover markers as
predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
J Natl Cancer Inst 2005; 97: 59–69.
5. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO
Clinical Practice Guidelines. Ann Oncol 2014; 25 (Suppl 3): iii124–iii137.
6. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS et al. American
Society of Clinical Oncology executive summary of the clinical practice guideline update on the
role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221–1227.
7. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD et al. Alpha emitter radium-
223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213–223.
8. Seibel MJ. Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract
Oncol 2005; 2: 504–517; quiz 1p following 33.
9. Jung K, Lein M. Bone turnover markers in serum and urine as diagnostic, prognostic and
monitoring biomarkers of bone metastasis. Biochim Biophys Acta 2014; 1846: 425–438.
10. Hlaing TT, Compston JE. Biochemical markers of bone turnover—uses and limitations. Ann
Clin Biochem 2014; 51: 189–202.
11. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin
Biochem Rev 2005; 26: 97–122.
Bone remodeling markers in bone metastatic disease
A Ferreira et al
BoneKEy Reports | APRIL 2015 7
12. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC et al. Prospective
evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in
predicting bone metastases status. J Clin Oncol 2002; 20: 850–856.
13. Carl A, Burtis DEB. Tiezt Fundamentals of Clinical Chemistry and Molecular Diagnosis. 7th edn
(Elsevier: Amsterdam, 2014).
14. Kyvernitakis I, Rachner TD, Urbschat A, Hars O, Hofbauer LC, Hadji P. Effect of aromatase
inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral
density in women with breast cancer. J Cancer Res Clin Oncol 2014; 140: 1671–1680.
15. Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of
zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive
postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin
Endocrinol Metab 2013; 98: 3206–3212.
16. Hsu YH, Kiel DP. Clinical review: genome-wide association studies of skeletal phenotypes:
what we have learned and where we are headed. J Clin Endocrinol Metab 2012; 97:
E1958–E1977.
17. Lombardi G, Lanteri P, Colombini A, Banfi G. Blood biochemical markers of bone turnover: pre-
analytical and technical aspects of sample collection and handling. Clin Chem Lab Med 2012;
50: 771–789.
18. Schafer AL, Vittinghoff E, Ramachandran R, Mahmoudi N, Bauer DC. Laboratory repro-
ducibility of biochemical markers of bone turnover in clinical practice. Osteoporos Int 2010; 21:
439–445.
19. Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P et al. National Bone Health
Alliance Bone Turnover Marker Project: current practices and the need for US
harmonization, standardization, and common reference ranges. Osteoporos Int 2012; 23:
2425–2433.
20. Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T et al. International
Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory
Medicine position on bone marker standards in osteoporosis. Clin Chem Lab Med 2011; 49:
1271–1274.
21. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A et al. Markers of bone
turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for
international reference standards. Osteoporos Int 2011; 22: 391–420.
22. Naylor K, Eastell R. Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol 2012; 8:
379–389.
23. Wheater G, Elshahaly M, Tuck SP, Datta HK, van Laar JM. The clinical utility of bone marker
measurements in osteoporosis. J Transl Med 2013; 11: 201.
24. Garnero P, Vergnaud P, Hoyle N. Evaluation of a fully automated serum assay for total
N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 2008; 54:
188–196.
25. Marshall LA, Cain DF, Dmowski WP, Chesnut 3rd CH . Urinary N-telopeptides to monitor bone
resorption while on GnRH agonist therapy. Obstet Gynecol 1996; 87: 350–354.
26. Garnero P, Gineyts E, Riou JP, Delmas PD. Assessment of bone resorption with a new marker
of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 1994;
79: 780–785.
27. Cremers S, Sepulveda JL, Turk A. Clinical Chemistry: Endocrine (Thyroid, Pituitary, Adrenal,
Bone, Pancreas, Reproductive) and cathecolamines. In: Spitalnik SL, Arinsburg SA, Jhang JS
(eds), Clinical pathology- Board Review. Philadelphia, PA, USA, 2015.
28. Christgau S. Circadian variation in serum CrossLaps concentration is reduced in fasting
individuals. Clin Chem 2000; 46: 431.
29. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone
turnover. Clin Chem 2001; 47: 1443–1450.
30. Hird A, Chow E, Zhang L, Wong R, Wu J, Sinclair E et al. Determining the incidence of pain flare
following palliative radiotherapy for symptomatic bone metastases: results from three canadian
cancer centers. Int J Radiat Oncol Biol Phys 2009; 75: 193–197.
31. Wu K, Lin TH, Liou HC, Lu DH, Chen YR, Fu WM et al. Dextromethorphan inhibits osteoclast
differentiation by suppressing RANKL-induced nuclear factor-kappaB activation. Osteoporos
Int 2013; 24: 2201–2214.
32. Robertson KM, Norgard M, Windahl SH, Hultenby K, Ohlsson C, Andersson G et al.
Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in
osteoclast differentiation and activation. J Bone Miner Res 2006; 21: 1276–1287.
33. Fernandez-Murga ML, Vinue A, Caeiro JR, Guede D, Tarin JJ, Andres V et al. Impact of
estrogens on atherosclerosis and bone in the apolipoprotein E-deficient mouse model.
Menopause 2014; 22: 428–436.
34. Peng J, Lai ZG, Fang ZL, Xing S, Hui K, Hao C et al. Dimethyloxalylglycine prevents bone loss in
ovariectomized C57BL/6J mice through enhanced angiogenesis and osteogenesis. PLoS ONE
2014; 9: e112744.
35. Gualeni B, de Vernejoul MC, Marty-Morieux C, De Leonardis F, Franchi M, Monti L et al.
Alteration of proteoglycan sulfation affects bone growth and remodeling. Bone 2013; 54: 83–91.
36. Ohlsson C, Engdahl C, Fak F, Andersson A, Windahl SH, Farman HH et al. Probiotics protect
mice from ovariectomy-induced cortical bone loss. PLoS ONE 2014; 9: e92368.
37. Tomita M, Katsuyama H, Watanabe Y, Okuyama T, Fushimi S, Ishikawa T et al. Does
methamphetamine affect bone metabolism? Toxicology 2014; 319: 63–68.
38. Liu S, Song W, Boulanger JH, Tang W, Sabbagh Y, Kelley B et al. Role of TGF-beta in a mouse
model of high turnover renal osteodystrophy. J Bone Miner Res 2014; 29: 1141–1157.
39. Gabet Y, Baniwal SK, Leclerc N, Shi Y, Kohn-Gabet AE, Cogan J et al. Krox20/EGR2 deficiency
accelerates cell growth and differentiation in the monocytic lineage and decreases bone mass.
Blood 2010; 116: 3964–3971.
40. Chiusaroli R, Knobler H, Luxenburg C, Sanjay A, Granot-Attas S, Tiran Z et al. Tyrosine
phosphatase epsilon is a positive regulator of osteoclast function in vitro and in vivo. Mol Biol
Cell 2004; 15: 234–244.
41. Glorie L, Behets GJ, Baerts L, De Meester I, D’Haese PC, Verhulst A. DPP IV inhibitor treatment
attenuates bone loss and improves mechanical bone strength in male diabetic rats. Am J
Physiol Endocrinol Metab 2014; 307: E447–E455.
42. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC et al. Potent and selective
inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman
primate. J Bone Miner Res 2001; 16: 1739–1746.
43. Smith SY, Jolette J, Chouinard L, Komm BS. The effects of bazedoxifene in the ovariectomized
aged cynomolgus monkey. J Bone Miner Metab 2014; 33: 161–172.
44. Smith SY, Doyle N, Boyer M, Chouinard L, Saito H. Eldecalcitol, a vitamin D analog, reduces
bone turnover and increases trabecular and cortical bone mass, density, and strength in
ovariectomized cynomolgus monkeys. Bone 2013; 57: 116–122.
45. Smith SY, Recker RR, Hannan M, Muller R, Bauss F. Intermittent intravenous administration of
the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in
ovariectomized cynomolgus monkeys. Bone 2003; 32: 45–55.
46. Soung do Y, Gentile MA, Duong le T, Drissi H. Effects of pharmacological inhibition of cathepsin
K on fracture repair in mice. Bone 2013; 55: 248–255.
47. Papadimitropoulos A, Scherberich A, Guven S, Theilgaard N, Crooijmans HJ, Santini F et al.
A 3D in vitro bone organ model using human progenitor cells. Eur Cell Mater 2011; 21:
445–458; discussion 58.
48. Colleoni M, O’Neill A, Goldhirsch A, Gelber RD, Bonetti M, Thurlimann B et al. Identifying
breast cancer patients at high risk for bone metastases. J Clin Oncol 2000; 18: 3925–3935.
49. Diel IJ. Prognostic factors for skeletal relapse in breast cancer. Cancer Treat Rev 2001; 27:
153–157discussion 9–64.
50. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M et al. Latent bone metastasis in
breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67–78.
51. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V et al. Predicting the risk of bone
metastasis in prostate cancer. Cancer Treat Rev 2014; 40: 3–11.
52. Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF et al. Elevated bone
turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG
MA.14. J Clin Oncol 2011; 29: 3605–3610.
53. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer
progression: the missing link of tumor microenvironment. J Urol 2005; 173: 10–20.
54. Coleman R, Rathbone E, Marshall H, Wilson C, Brown J, Gossiel F et al. Vitamin D, but not bone
turnover markers, predict relapse in women with early breast cancer: an AZURE translational
study. Cancer Res 2012; 72: S6-4-S6-4.
55. Diel IJ, Solomayer EF, Seibel MJ, Pfeilschifter J, Maisenbacher H, Gollan C et al. Serum bone
sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone
metastasis. Clin Cancer Res 1999; 5: 3914–3919.
56. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C et al.
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009;
360: 679–691.
57. Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P et al. Zoledronic acid
(zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole
(ZO-FAST study): final 60-month results. Ann Oncol 2013; 24: 398–405.
58. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M et al. Breast-cancer
adjuvant therapy with zoledronic acid. N Engl J Med 2011; 365: 1396–1405.
59. Coleman R, Gnant M, Paterson A, Powles T, von Minckwitz G, Pritchard K et al. Abstract
S4–07: effects of bisphosphonate treatmenta on recurrence and cause-specific mortality in
women with early breast cancer: a meta-analysis of individual patient data from randomised
trials. Cancer Res 2014; 73: S4-07-S4-.
60. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic
breast cancer. J Clin Oncol 2004; 22: 2942–2953.
61. Body JJ, Dumon JC, Gineyts E, Delmas PD. Comparative evaluation of markers of bone
resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate
therapy. Br J Cancer 1997; 75: 408–412.
62. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone
turnover in patients with metastatic bone disease. Clin Chem 1995; 41: 1489–1494.
63. Wada N, Fujisaki M, Ishii S, Ikeda T, Kitajima M. Evaluation of bone metabolic markers in breast
cancer with bone metastasis. Breast Cancer 2001; 8: 131–137.
64. Joerger M, Huober J. Diagnostic and prognostic use of bone turnover markers. Recent results.
Cancer Res 2012; 192: 197–223.
65. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M et al. Predictive value of bone
resorption and formation markers in cancer patients with bone metastases receiving the
bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925–4935.
66. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast
cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist
2007; 12: 1035–1043.
67. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E et al. Normalization of bone
markers is associated with improved survival in patients with bone metastases from
solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113:
193–201.
68. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, double-
blind study of denosumab versus zoledronic acid in the treatment of bone metastases in
patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
J Clin Oncol 2011; 29: 1125–1132.
Bone remodeling markers in bone metastatic disease
A Ferreira et al
8 APRIL 2015 | www.nature.com/bonekey
69. Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B et al. Denosumab and bone-
metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3,
randomised, placebo-controlled trial. Lancet 2012; 379: 39–46.
70. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ et al. Randomized
active-controlled phase II study of denosumab efficacy and safety in patients with breast
cancer-related bone metastases. J Clin Oncol 2007; 25: 4431–4437.
71. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009; 8:
96–110.
72. Coleman RE, Wright J, Houston S, Agrawal R, Purohit OP-K, Hayward L et al. Randomized trial
of marker-directed versus standard schedule zoledronic acid for bone metastases from breast
cancer. J Clin Oncol 2012; 30: (suppl; abstr 511).
73. Amir E, Freedman O, Carlsson L, Dranitsaris G, Tomlinson G, Laupacis A et al. Randomized
feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous
pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol
2013; 36: 436–442.
74. Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E et al. A phase II,
multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic
breast cancer patients at low-risk of skeletal-related events. Breast Cancer Res Treat 2014;
144: 615–624.
75. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G et al. Efficacy and safety of
12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone
metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority
trial. Lancet Oncol 2013; 14: 663–670.
76. Hortobagyi GN, Lipton A, Chew HK, Gradishar WJ, Sauter NP, Mohanlal RW et al. Efficacy and
safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone
metastases from breast cancer: results of the OPTIMIZE-2 trial. J Clin Oncol 2014; 32: 5s
(suppl; abstr LBA9500^).
77. Gibiansky L, Sutjandra L, Doshi S, Zheng J, Sohn W, Peterson MC et al. Population
pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.
Clin Pharmacokinet 2012; 51: 247–260.
78. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E et al. Consensus on the utility of bone
markers in the malignant bone disease setting. Crit Rev Oncol Hematol 2011; 80: 411–432.
79. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG et al. Cabozantinib in
patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
J Clin Oncol 2013; 31: 412–419.
80. Hayes DF, Bast RC, Desch CE, Fritsche Jr. H , Kemeny NE, Jessup JM et al. Tumor marker
utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer
Inst 1996; 88: 1456–1466.
Bone remodeling markers in bone metastatic disease
A Ferreira et al
BoneKEy Reports | APRIL 2015 9
